LINKS
CONTACT & CONNECT

Headquarters:

19950 W Country Club Drive
7th Floor

Aventura, FL 33180

International Offices:

Germany

info@ipdanalytics.com

+1 (305) 662-8515

  • LinkedIn Social Icon
  • Twitter Social Icon
Asset 211.png

© 2019 by IPD Analytics | Privacy Policy

Our Executive Clinical Pharmacy team explains manufacturer life-cycle management strategies, including specific examples of successes and failures. 

 

Topics included in this episode:

  • Additional indications

  • New formulations

  • Next generation products

  • Different strengths

  • Bundling

  • Brand over generic strategies

  • Reimbursement incentives and coding strategies

  • Distribution channels

  • Co-pay assistance programs

  • Strategic partnerships

  • Authorized generics

IPD'S DRUG & CLINICAL REVIEW:

MANUFACTURER LIFE-CYCLE MANAGEMENT STRATEGIES

“What about new strengths or dosing regimens? We see that a lot too, don't we?"

 

“A very good example of this is Copaxone. So, the Copaxone 40-milligram three times weekly was launched in 2014, just over a year before the launch of competing generics for the original 20-milligram, once-daily formulation. In about a year, the 40-milligram formulation captured 70% of the market. This allowed Teva to continue to dominate the market following the launch of these generics with only minimal threat. Now that generics are on the market for the 40-milligram strength, Teva has used other life-cycle management tactics to maintain its brand Copaxone franchise.”